HUNTINGTON BEACH, Calif., May 23, 2026 — Leonhardt Ventures LLC announced today that technologies, inventions, and derivative product families associated with founder Howard J. Leonhardt and affiliated innovation programs have now contributed to the treatment of more than one million patients worldwide.
The milestone reflects over four decades of innovation spanning cardiovascular devices, regenerative medicine, bioelectric stimulation, intravascular lung, radiation catheters, structural heart technologies, catheter systems, stent grafts, percutaneous heart valves, and biologics therapies.
Leonhardt-associated technologies and programs have included:
• Polyurethane balloon catheter technologies
• MyoCath™, VascuStim TM, Bioheart TM and MyoCell™ regenerative cardiovascular therapy technologies
• Aortic stent graft technologies and derivative product platforms including aortic stent based circulatory assist pumps.
“We are deeply grateful to the physicians, engineers, nurses, scientists, patients, strategic partners, and investors who helped bring these innovations to patients worldwide,” said Howard J. Leonhardt, Executive Chairman of Leonhardt Ventures LLC and Lionheart Health, Inc. “Crossing the one million patient milestone reflects decades of perseverance, collaboration, and commitment to technologies designed to restore health, extend vitality, and improve quality of life.”
Leonhardt Ventures LLC estimates that its technologies and affiliated product platforms have collectively generated billions of dollars in downstream revenues for licensees, acquirers, strategic partners, clinics and affiliated commercialization entities over the past four decades.
Current Leonhardt Ventures and Lionheart Health initiatives are focused on:
• Bioelectric stimulation-driven regenerative medicine including non-invasive and invasive implant devices.
• Healthspan and longevity optimization
• Klotho-enhanced regenerative therapies
• AI-guided personalized wellness systems
About Leonhardt Ventures LLC
Leonhardt Ventures LLC founded in 1982 is a California-based innovation and commercialization company focused on regenerative medicine, cardiovascular technologies, bioelectric stimulation, longevity science, and advanced wellness systems. The organization and its affiliated accelerator programs have helped support numerous startups, clinical initiatives, and medical technology platforms over the past four decades. Leonhardt Ventures LLC has over 800 patent claims issued, licensed, optioned or in process.
Media Contact:
Leonhardt Ventures LLC
21060 Pacific City Cir 6115
Huntington Beach, CA 92648
www.leonhardtventures.com
Forward-Looking Statements